These studies collectively aim to evaluate the efficacy, safety, and feasibility of [177Lu]Lu-PSMA RLT in the neoadjuvant setting, potentially improving outcomes for patients with high-risk prostate cancer. The gene discussed is FOLH1; the disease is prostate cancer.